Cytoprotective effects of bilirubin;Cytoprotektivní účinky bilirubinu

Casopis Lekaru Ceskych

Volumn 144, Issue SUPPL. 1, 2005, Pages 58-62

  Vítek, Libor ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b U Nemocnice 2   (Czech Republic)

Author keywords

Antioxidant; Atherosclerosis; Bilirubin; Ischemic heart disease

Indexed keywords

ANTIOXIDANT; BILIRUBIN; HEME;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL PROTECTION; GILBERT DISEASE; HUMAN; HYPERBILIRUBINEMIA; ISCHEMIC HEART DISEASE; KERNICTERUS; NEWBORN JAUNDICE; PROTEIN DEGRADATION; REACTION ANALYSIS; REVIEW; CARDIOVASCULAR DISEASE; CHEMISTRY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

BILIRUBIN; CARDIOVASCULAR DISEASES; CYTOPROTECTION; HUMANS; OXIDATIVE STRESS;

EID: 18744416605     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Stocker, R., Yamamoto, Y., McDonagh, A. F. et al.: Bilirubin is an antioxidant of possible physiological importance. Science, 1987, 235, s. 1043-1036.
2. Wu, T.-W., Fung, K. P., Wu, J. et al.: Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem. Pharmacol., 1996, 51, s. 859-862.
3. Willis, D., Moore, A. R., Frederik, R., Willoughby, D. A.: Heme oxygenase: a novel target for the modulation of the inflammatory response. Nature Med., 1996, 2, s. 87-90.
4. Malagami, T., Toyomura, K., Kinoshita, T., Morisawa, S.: A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim. Biophys. Acta, 1993, 1158, s. 189-183.
5. Tögl-Leimuller, A., Egger, G., Porta, S.: Albumin as a one way transport vehicle into sites of inflammation. Exp. Pathol., 1986, 30, s. 91-96.
6. Baranano, D. E., Rao, M., Ferris, C. D., Snyder, S. H.: Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad Sci., USA, 2002, 99, s. 16093-16098.
7. Maines, M. D. The heme oxygenase system: a regulator of second messenger gases. Annu Rev. Pharmacol. Toxicol., 1997, 37, s. 517-554.
8. Leffler, C. W., Nasjletti, A., Yu, C. et al.: Carbon monoxide and cerebral microvascular tone in newborn pigs. Am. J. Physiol., 1999, 276, s. H1641-H1646.
9. Pannen, B. H., Bauer, M.: Differential regulation of hepatic arterial and portal venous vascular resistance by nitric oxide and carbon monoxide in rats. Life Sci., 1998, 62, s. 2025-2033.
10. Smith, D. W., Hopper, A. O., Shahin, S. M. et al.: Neonatal bilirubin production estimated from "end-tidal" carbon monoxide concentration. J. Pediatr. Gastroenterol. Nutr., 1984, 3, s. 77-80.
11. Clark, J. E., Foresti, R., Sarathchandra, P. et al.: Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am. J. Physiol. Heart Circ. Physiol., 2000, 278, s. H643-H651.
12. Raju, V. S., Imai, N., Liang, C. S.: Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. J. Mol. Cell Cardiol., 1999, 31, s. 1581-1589.
13. Sharma, H. S., Manlik, N., Gho, B. C. et al.: Coordinated expression of heme oxygenase-1 and ubiquitin in the porcine heart subjected to ischemia and reperfusion. Mol. Cell Biochem., 1996, 157, s. 111-116.
14. Raju, V. S., Maines, M. D.: Renal ischemia/reperfusion up-regulates heme oxygenase-1 (HSP32) expression and increases cGMP in rat heart. J. Pharm. Exp. Ther., 1996, 277, s. 1814-1822.
15. Ishizaka, N., de Leon, H., Laursen, J. B. et al. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation, 1997, 96, s. 1923-1929.
16. Sharma, S. C.: Serum unconjugated bilirubin and free fatty acids in acute myocardial infarction and angina. J. Ass. Phys. India, 1985, 33, s. 473-475.
17. Wang, L. J., Lee, T. S., Lee, F. Y. et al.: Expression of heme oxygenase-1 in atherosclerotic lesions. Am. J. Pathol., 1998, 152, s. 711-720.
18. Abraham, N. G., Lavrovsky, Y., Schwartzman, M. L. et al.: Transfection of the human gene heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity. Proc. Natl. Acad. Sci. USA, 1995, 92, s. 6798-6802.
19. Hanckock, W. W., Buelow, R., Sayegh, M. H., Turka, L. A.: Antibody-induced transplant arteriosclerosis is prevented by graft expression of antioxidant and antiapoptotic genes. Nat. Med., 1998, 4, s. 1392-1396.
20. Taji, T. Y., Wu, X., Lau, C. K. et al.: Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation, 2003, 107, s. 2623-2629.
21. Kato, Y., Shimazu, M., Kondo, M. et al.: Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hematology, 2003, 38, s. 364-373.
22. Ishikawa, K., Sugawara, D., Wang, X. et al.: Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Cirk. Res., 2001, 88, s. 506-512.
23. Ishikawa, K., Sugawara, D., Goto, J. et al.: Heme oxygenase-1 inhibits atherogenesis in Watanabe heritable hyperlipidemic rabbits. Circulation, 2001, 104, s. 1831-1836.
24. Juan, S. H., Lee, T. S., Tseng, K. W. et al.: Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2001, 104, s. 1519-1525.
25. Duckers, H. J., Boehm, M., True, A. L. et al.: Heme oxygenase-1 protects against vascular constriction and proliferation. Nat. Med., 2001, 7, s. 693-698.
26. Otterbein, L. E., Kolls, J. K., Mantel, L. L. et al.: Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J. Clin. Invest., 1999, 103, s. 1047-1054.
27. Okinaga, S., Takahashi, K., Takeda, K. et al.: Regulation of human heme oxygenase-1 gene expression under thermal stress. Blood, 1996, 87, s. 5074-5084.
28. Yamada, N., Yamaya, M., Okinaga, S. et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet., 2000, 66, s. 187-195.
29. Yamaha, M., Nakayama, K., Ebihara, S. et al.: Relationship between microsatellite polymorphism in the haem oxygenase-1 gene promoter and longevity of the normal Japanese population. J. Med. Genet., 2003, 40, s. 146-148.
30. Schillinger, M., Exner, M., Mlekusch, W. et al.: Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb. Res., 2002, 106, s. 131-136.
31. Exner, M., Schillinger, M., Minar, E. et al.: Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J. Endovasc. Ther., 2001, 8, s. 433-440.
32. Kaneda, H., Ohno, M., Tagichi, J. et al.: Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler. Thromb. Vasc. Biol., 2002, 22, s. 1680-1685.
33. Chen, Y. H., Lin, S. J., Lin, M. W. et al.: Microsatellite polymorphism in promoter of heme-oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet., 2002, 111, s. 1-8.
34. Furchgott, R. F., Jothianandan, D.: Endothelium-dependent and independent vasodilatation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessel, 1991, 28, s. 52-61.
35. Brune, B., Ullrich, V.: Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol. Pharmacol., 1987, 32, s. 497-504.
36. Morita, T., Kourembanas, S.: Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J. Clin. Invest., 1995, 96, s. 2676-2682.
37. Ishizaka, N., de Leon, H., Laursen, J. B. et al.: Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation, 1997, 96, s. 1923-1929.
38. Moore, B. A., Otterbein, L. E., Turler, A. et al.: Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. Gastroenterology, 2003, 124, s. 377-391.
39. Henningsson, R., Alm, P., Ekstrom, P., Lundquist, I.: Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. Diabetes, 1999, 48, s. 66-76.
40. Paredi, P., Biernacki, W., Invernizzi, G. et al.: Exhaled carbon monoxide levels elevated in diabetes and correlated with glucose concentration in blood: a new test for monitoring the disease? Chest, 1999, 116, s. 1007-1011.
41. Zayasu, K., Sekizawa, K., Okinaga, S. et al.: Increased carbon monoxide in exhaled air of asthmatic patients. Am. J. Respir. Crit. Care Med., 1997, 156, s. 1140-1143.
42. Paredi, P., Shah, P. L., Montuschi, P. et al.: Increased carbon monoxide in exhaled air of patients with cystic fibrosis. Thorax, 1999, 54, s. 917-920.
43. Scharte, M., Bone, H. G., van Aken, H., Meyer, J.: Increased carbon monoxide in exhaled air of critically ill patients. Biochem. Biophys. Res. Commun., 2000, 267, s. 423-426.
44. Abraham, N., Selby, W., Lazarus, R., Solomon, M.: Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. J. Gastroenterol. Hepatol., 2003, 18, s. 139-146.
45. Mitchell, S. A., Thyssen, M., Orchard, T. R. et al.: Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut, 2002, 51, s. 567-573.
46. Conde-Agudelo, A., Althabe, F., Belizan, J. M., Kafury-Goeta, A. C.: Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am. J. Obstet. Gynecol., 1999, 181, s. 1026-1035.
47. Allam, M. F., del Castillo, A. S., Navajas, R. F.: Parkinson's disease, smoking and family history: meta-analysis. Eur. J. Neurol., 2003, 10, s. 59-62.
48. Otterbein, L. E., Mantell, L. L., Choi, A. M.: Carbon monoxide provides protection against hyperoxic lung injury. Am. J. Physiol., 1999, 276, s. L688-L694.
49. Fujita, T., Toda, K., Karimova, A. et al.: Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nat. Med., 2001, 7, s. 598-604.
50. Kyokane, T., Norimizu, S., Taniai, H. et al.: Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. Gastroenterology, 2001, 120, s. 1227-1240.
51. Motterlini, R., Clark, J. E., Foresti, R. et al.: Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ. Res., 2002, 90, s. E17-E24.
52. Foresti, R., Hammad, J., Clark, J. E. et al.: Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molekule. Br. J. Pharmacol., 2004, 142, s. 453-460.
53. Stein, A. B., Guo, Y., Tan, W., et al.: Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J. Mol. Cell Cardiol., 2005, 38, s. 127-134.
54. Heyman, E., Ohlsson, A., Girscheck, P.: Retinopathy of prematurity and bilirubin. N. Engl. J. Med., 1989, 320, s. 256.
55. Yeo, K. L., Perlman, M., Hao, Y., Mullaney, P.: Outcomes of extremely premature infants related to their peak serum bilirubin concentrations and exposure to thein peak serum bilirubin concentrations and exposure to phototherapy. Pediatrics, 1998, 102, s. 1426-1431.
56. Benaron, D. A., Bowen, F. W.: Variation of initial serum bilirubin rise in newborn infants with type of ilness. Lancet, 1991, 338, s. 78-81.
57. Hegyi, T., Goldie, E., Hiatt, M.: The protective role of bilirubin in oxygen-radical diseases of the preterm infant. J. Perinatol., 1994, 14, s. 296-300.
58. Wiedemann, M., Kontush, A., Finckh, B. et al.: Neonatal blood plasma is less susceptible to oxidation than adult plasma owing to its higher content of bilirubin and lower content of oxidizable fatty acids. Pediatr. Res., 2003, 53, s. 843-849.
59. Dailly, E., Urien, S., Barre, J. et al.: Role of bilirubin in the regulation of the total peroxyl radical trapping antioxidant aktivity of plasma in sickle cell disease. Biochem. Biophys. Res. Commun., 1998, 248, s. 303-306.
60. Ilzecka, J., Stelmasiak, Z.: Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg., 2003, 105, s. 237-240.
61. Schwertner, H. A., Vitek, L.: Low serum bilirubin concentrations and risk of rheumatoid arthritis and lupus nephropathy. Clin. Chem., 2004, 50, s. A53-A53, Part. 2, Suppl. S.
62. Vítek, L., Novotný, L., Muchová, L. et al.: Decreased levels of serum bilirubin as a risk factor in lupus nephropathy. J. Am. Soc. Nephrol., 2003, 14, s. 381A.
63. Oren, D. A., Desan, P. H., Boutros, N. et al.: Effects of light on low nocturnal bilirubin in winter depression: a preliminary report. Biol. Psychiatry, 2002, 51, s. 422-425.
64. Temme, E. H., Zhang, J., Schoulen, E. G., Kesteloot, H.: Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Cause Control., 2001, 12, s. 887-894.
65. Wei, M., Schwertner, H. A., Gibbons, L. W. et al.: Low fasting serum bilirubin as a predictor of cancer mortality in men. Hepatology, 2000, 32, s. 427A.
66. Ko, W. F., Helzlsouer, K. J., Comstock, G. W.: Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J. Natl. Cancer Inst., 1994, 86, s. 1874-1875.
67. Zucker, S. D., Horn, P. S., Sherman, K. E.: Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology, 2004, 40, s. 827-835.
68. Schwertner, H. A., Jackson, W. G., Tolan, G.: Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem., 1994, 40, s. 18-23.
69. Hopkins, P. N., Wu, L. L., Hunt, S. C. et al.: Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 1996, 16, s. 250-255.
70. Vítek, L., Jirsa, Jr. M., Brodanová, M. et al.: Gilbert syndrome and ischemic hear disease: a protective effect of elevated bilirubin levels. Atherosclerosis, 2002, 160, s. 449-456.
71. Vítek, L., Novotný, L., Spáčil, J. et al.: The role of elevated serum bilirubin levels on carotid atherosclerosis. Hepatology, 2003, 38, s. 383A.
72. Novotný, L., Vítek, L.: Inverse relationship between serum bilirubin and atherosclerosis in men. A meta-analysis of published results. Exp. Biol. Med., 2003, 228, s. 568-571.
73. Yamaguchi, T., Shioji, I., Sugimoto, A. et al.: Chemical structure of a new family of bile pigments from human urine. J. Biochem., 1994, 116, s. 298-303.
74. Shimomura, H., Ogawa, H., Takazoe, K. et al.: Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events. Am. J. Cardiol., 2002, 90, s. 108-111.
75. Morita, Y., Takahashi, H., Kamihata, H. et al.: Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases after spasm provocation tests in patients with coronary spastic angina. Int. J. Cardiol., 2001, 80, s. 243-250.
76. Hokamaki, J., Kawano, H., Yoshimura, M. et al.: Urinary biopyrrins levels are elevated in relation to severity of heart failure. J. Am. Coll. Cardiol., 2004, 43, s. 1880-1885.
77. Kozaki, N., Shimizu, S., Chijiiwa, K. et al.: Bilirubin as an anti-oxidant for surgical stress: a preliminary report of bilirubin oxidative metabolites. HPB Surg., 1999, 11, s. 241-248.
78. Tsujinaka, T., Fujita, J., Morimoto, T. et al.: Increased urinary excretion of bilirubin metabolites in association with hyperbilirubinemia after esophagectomy. Surg. Today, 1998, 28, s. 1119-1123.
79. Tsukahara, H., Shibata, R., Ohshima, Y. et al.: Oxidative stress and altered antioxidant defense in children with acute exacerbation of atopic dermatitis. Life Sci., 2003, 72, s. 2509-2516.
80. Otani, K., Shimizu, S., Chijiiwa, K. et al.: Increased urinary excretion of bilirubin oxidative metabolites in septic patiens: a new marker for oxidative stress. J. Surg. Res., 2001, 96, s. 44-49.
81. Yoshida, R., Ogawa, Y., Shioji, I. et al.: Urinary 8-oxo-7, 8-dihydro-2′-deoxyguanosine and biopyrrins levels among construction workers with asbestos exposure history. Ind. Health, 2001, 39, s. 186-188.
82. Yamaguchi, T., Shioji, I., Sugimoto, A., Yamaoka, M.: Psychological stress increases bilirubin metabolites in human urine. Biochem. Biophys. Res. Commun., 2002, 293, s. 517-520.
83. Tsukahara, H., Haruta, T., Todoroki, Y. et al.: Oxidant and antioxidant activities in childhood meningitis. Life Sci., 2002, 71, s. 2797.
84. Kimpara, T., Takeda, A., Yamaguchi, T. et al.: Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol. Aging, 2000, 21, s. 551-554.
85. Vítek, L., Kráslová, I., Muchová, L. et al.: Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. FASEB J., 2004, 18, s. A1189.
86. th edition. Eds. Bennett JC, Plum F, WB Saunders Comp 1996, Philadelphia, USA.
87. Mayer, M.: Association of serum bilirubin concentration with risk of coronary artery disease. Clin. Chem., 2000, 46, s. 1723-1727.
88. Motterlini, R., Green, C. J., Foresti, R.: Regulation of heme oxygenase-1 by redox signals involving nitric oxide. Antioxid. Redox. Signal., 2002, 4, s. 615-624.
89. Mělo, L. G., Agrawal, R., Zhang, L. et al.: Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation, 2002, 105, s. 602-607.
90. Horvath, I., Donnelly, L. E., Kiss, A. et al.: Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax, 1998, 53, s. 668-672.